Cognitive Remediation for Neuropsychological Impairment in Compulsive Hoarding

Early Phase 1CompletedNCT01451697

Hartford Hospital20 enrolled

Overview

The primary aim of this pilot randomized controlled trial is to examine whether cognitive remediation, compared to a placebo, improves attention and related cognitive functions in patients with compulsive hoarding. The primary hypothesis is that compulsive hoarding patients who are treated with cognitive remediation will demonstrate improved cognitive skills at post-treatment compared to patients receiving placebo. This will be especially true of attention; memory and executive function skills may also be improved.

The primary aim of this pilot randomized controlled trial is to examine whether cognitive remediation, compared to a placebo, improves attention and related cognitive functions in patients with compulsive hoarding. Previous research has demonstrated that hoarders have diminished neuropsychological abilities, particularly in the areas of attention, memory, and executive function; and that cognitive remediation improves those functions in populations that are similarly impaired, such as in individuals with schizophrenia. The investigators will thus randomize 20 patients with compulsive hoarding to receive either cognitive remediation or a placebo condition. Before and after treatment, the investigators aim to assess the effects of cognitive remediation on neuropsychological functioning and hoarding severity. The primary specific aim is to examine whether cognitive remediation improves cognitive function in compulsive hoarders. The investigators hypothesize that compulsive hoarding patients who are treated with cognitive remediation will demonstrate improved cognitive skills at post-treatment compared to patients receiving placebo. This will be especially true of attention; memory and executive function skills may also be improved. A secondary, exploratory aim is to examine whether cognitive remediation improves hoarding severity, compared to placebo. The ultimate goal of this research is to determine the feasibility and appropriateness of pursuing larger-scale studies of the promising new approach of combining cognitive remediation with other treatments for compulsive hoarding-particularly cognitive-behavioral therapy (CBT).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Conditions

Hoarding Disorder Attentional Impairment

Interventions

Cognitive RemediationBEHAVIORAL

A computerized cognitive remediation program focused on attentional training will be used.

Control (Placebo)BEHAVIORAL

The control condition will involve relaxation training.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * be over 18 years of age, * have a current primary diagnosis of hoarding disorder * have no untreated and/or unstable concurrent psychiatric diagnoses * have a score on the ADHDSS that is one standard deviation or more above the mean * have an Attentional Composite score on the computerized battery of neuropsychological tests (Doniger, 2010) that is one standard deviation or more below the mean * be stable on all psychotropic medications during and up to four weeks preceding enrollment in the study Exclusion Criteria: * currently taking any cognitive enhancers or stimulants * people with a history of Multiple Sclerosis, Traumatic Brain Injury, loss of consciousness lasting more than 5 minutes, seizures, dementia, or other organic brain-related disorders * current Alcohol or Substance Abuse and/or a history of Alcohol or Substance Dependence

Locations (1)

Anxiety Disorders Center, Institute of Living/Hartford

Hartford, Connecticut, United States

Outcomes

Primary Outcomes

Continuous Performance Task (computerized version): change from Baseline in Attentional Functioning at 8 Weeks

This measure is a computerized assessment of attention, memory, and executive functioning. The investigators will use this measure to assess change in those cognitive domains between Baseline (Week 0) and Endpoint (Week 8).

Time frame: Week 0 (Baseline) and Week 8 (Endpoint)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.